Search

Your search keyword '"Zafar, Faiza"' showing total 218 results
Start Over Author "Zafar, Faiza"
218 results on '"Zafar, Faiza"'

2. Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment

Author

Siegel, David S, Schiller, Gary J, Samaras, Christy, Sebag, Michael, Berdeja, Jesus, Ganguly, Siddhartha, Matous, Jeffrey, Song, Kevin, Seet, Christopher S, Talamo, Giampaolo, Acosta-Rivera, Mirelis, Bar, Michael, Quick, Donald, Anz, Bertrand, Fonseca, Gustavo, Reece, Donna, Pierceall, William E, Chung, Weiyuan, Zafar, Faiza, Agarwal, Amit, and Bahlis, Nizar J

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Sciences, Oncology and Carcinogenesis, Hematology, Clinical Research, Rare Diseases, Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Aged, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Female, Humans, Lenalidomide, Male, Multiple Myeloma, Neoplasm Recurrence, Local, Progression-Free Survival, Thalidomide, Immunology, Cardiovascular medicine and haematology, Clinical sciences, Oncology and carcinogenesis
Abstract

Patients with multiple myeloma who have relapsed after or become refractory to lenalidomide in early treatment lines represent a clinically important population in need of effective therapies. The safety and efficacy of pomalidomide, low-dose dexamethasone, and daratumumab was evaluated in lenalidomide-pretreated patients with relapsed or refractory multiple myeloma (RRMM) after one to two prior treatment lines in the phase 2 MM-014 study. Patients received pomalidomide 4 mg daily from days 1-21 and dexamethasone 40 mg weekly (28-day cycles). Daratumumab 16 mg/kg was administered per label. Primary endpoint was overall response rate (ORR); secondary endpoints included progression-free survival (PFS) and safety. Per protocol, all patients (N = 112) had received lenalidomide in their most recent prior regimen (75.0% lenalidomide refractory). ORR was 77.7% (76.2% in lenalidomide-refractory patients); median follow-up was 17.2 months. Median PFS was not reached (1-year PFS rate 75.1%). The most common hematologic grade 3/4 treatment-emergent adverse event was neutropenia (62.5%). Grade 3/4 infections were reported in 31.3% of patients, including 13.4% with grade 3/4 pneumonia. These results demonstrate the safety and efficacy of pomalidomide-based therapy as early as second line in patients with RRMM, even immediately after lenalidomide failure, indicating that switching from the immunomodulatory agent class is not necessary.

Published
2020

3. Pomalidomide plus low‐dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure

Author

Siegel, David S, Schiller, Gary J, Song, Kevin W, Agajanian, Richy, Stockerl‐Goldstein, Keith, Kaya, Hakan, Sebag, Michael, Samaras, Christy, Malek, Ehsan, Talamo, Giampaolo, Seet, Christopher S, Mouro, Jorge, Pierceall, William E, Zafar, Faiza, Chung, Weiyuan, Srinivasan, Shankar, Agarwal, Amit, and Bahlis, Nizar J

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Clinical Trials and Supportive Activities, Cancer, Hematology, Rare Diseases, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Disease-Free Survival, Female, Humans, Lenalidomide, Male, Middle Aged, Multiple Myeloma, Survival Rate, Thalidomide, pomalidomide, dexamethasone, lenalidomide, multiple myeloma, refractory, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Abstract

Patients with relapsed/refractory multiple myeloma (RRMM) for whom the benefits of lenalidomide have been exhausted in early treatment lines need effective therapies. In cohort A of the phase 2 MM-014 trial, we examined the safety and efficacy of pomalidomide plus low-dose dexamethasone immediately after lenalidomide-based treatment failure in patients with RRMM and two prior lines of therapy. Pomalidomide 4 mg was given on days 1 to 21 of 28-day cycles. Dexamethasone 40 mg (20 mg for patients aged >75 years) was given on days 1, 8, 15 and 22 of 28-day cycles. The primary endpoint was overall response rate (ORR), and secondary endpoints included progression-free survival (PFS), overall survival (OS) and safety. The intention-to-treat population comprised 56 patients; all received prior lenalidomide (87·5% lenalidomide refractory) and 39 (69·6%) received prior bortezomib. ORR was 32·1% (28·2% in the prior-bortezomib subgroup). Median PFS was 12·2 months (7·9 months in the prior-bortezomib subgroup). Median OS was 41·7 months (38·6 months in the prior-bortezomib subgroup). The most common grade 3/4 treatment-emergent adverse events were anaemia (25·0%), pneumonia (14·3%) and fatigue (14·3%). These findings support earlier sequencing of pomalidomide-based therapy in lenalidomide-pretreated patients with RRMM, including those who have become refractory to lenalidomide. Trial registration: www.ClinicalTrials.gov identifier NCT01946477.

Published
2020

8. OA-27 Single cell transcriptomics reveals the impact of tumor cell interactions with the bone marrow immune microenvironment in the progression of multiple myeloma

Author

Sudha, Parvathi, primary, Zaid, Mohammad Abu, additional, Johnson, Travis, additional, Chopra, Vivek, additional, Santos, Cedric Dos, additional, Nixon, Michael, additional, Zafar, Faiza, additional, Hamidi, Habib, additional, Suvannasankha, Attaya, additional, Farag, Sherif, additional, Lee, Kelvin, additional, Abonour, Rafat, additional, and Walker, Brian, additional

Published
2023
Full Text
View/download PDF

13. Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry

Author

Rifkin, Robert M., Jagannath, Sundar, Durie, Brian G.M., Narang, Mohit, Terebelo, Howard R., Gasparetto, Cristina J., Toomey, Kathleen, Hardin, James W., Wagner, Lynne, Parikh, Kejal, Abouzaid, Safiya, Srinivasan, Shankar, Kitali, Amani, Zafar, Faiza, and Abonour, Rafat

Published
2018
Full Text
View/download PDF

15. Supplementary Table 2 from Overcoming the Response Plateau in Multiple Myeloma: A Novel Bortezomib-Based Strategy for Secondary Induction and High-Yield CD34+ Stem Cell Mobilization

Author

Niesvizky, Ruben, primary, Mark, Tomer M., primary, Ward, Maureen, primary, Jayabalan, David S., primary, Pearse, Roger N., primary, Manco, Megan, primary, Stern, Jessica, primary, Christos, Paul J., primary, Mathews, Lena, primary, Shore, Tsiporah B., primary, Zafar, Faiza, primary, Pekle, Karen, primary, Xiang, Zhaoying, primary, Ely, Scott, primary, Skerret, Donna, primary, Chen-Kiang, Selina, primary, Coleman, Morton, primary, and Lane, Maureen E., primary

Published
2023
Full Text
View/download PDF

16. Supplementary Figure 1 from Overcoming the Response Plateau in Multiple Myeloma: A Novel Bortezomib-Based Strategy for Secondary Induction and High-Yield CD34+ Stem Cell Mobilization

Author

Niesvizky, Ruben, primary, Mark, Tomer M., primary, Ward, Maureen, primary, Jayabalan, David S., primary, Pearse, Roger N., primary, Manco, Megan, primary, Stern, Jessica, primary, Christos, Paul J., primary, Mathews, Lena, primary, Shore, Tsiporah B., primary, Zafar, Faiza, primary, Pekle, Karen, primary, Xiang, Zhaoying, primary, Ely, Scott, primary, Skerret, Donna, primary, Chen-Kiang, Selina, primary, Coleman, Morton, primary, and Lane, Maureen E., primary

Published
2023
Full Text
View/download PDF

17. Supplementary Table 1 from Overcoming the Response Plateau in Multiple Myeloma: A Novel Bortezomib-Based Strategy for Secondary Induction and High-Yield CD34+ Stem Cell Mobilization

Author

Niesvizky, Ruben, primary, Mark, Tomer M., primary, Ward, Maureen, primary, Jayabalan, David S., primary, Pearse, Roger N., primary, Manco, Megan, primary, Stern, Jessica, primary, Christos, Paul J., primary, Mathews, Lena, primary, Shore, Tsiporah B., primary, Zafar, Faiza, primary, Pekle, Karen, primary, Xiang, Zhaoying, primary, Ely, Scott, primary, Skerret, Donna, primary, Chen-Kiang, Selina, primary, Coleman, Morton, primary, and Lane, Maureen E., primary

Published
2023
Full Text
View/download PDF

18. Supplementary Figure 2 from Overcoming the Response Plateau in Multiple Myeloma: A Novel Bortezomib-Based Strategy for Secondary Induction and High-Yield CD34+ Stem Cell Mobilization

Author

Niesvizky, Ruben, primary, Mark, Tomer M., primary, Ward, Maureen, primary, Jayabalan, David S., primary, Pearse, Roger N., primary, Manco, Megan, primary, Stern, Jessica, primary, Christos, Paul J., primary, Mathews, Lena, primary, Shore, Tsiporah B., primary, Zafar, Faiza, primary, Pekle, Karen, primary, Xiang, Zhaoying, primary, Ely, Scott, primary, Skerret, Donna, primary, Chen-Kiang, Selina, primary, Coleman, Morton, primary, and Lane, Maureen E., primary

Published
2023
Full Text
View/download PDF

19. Supplementary Table 3 from Overcoming the Response Plateau in Multiple Myeloma: A Novel Bortezomib-Based Strategy for Secondary Induction and High-Yield CD34+ Stem Cell Mobilization

Author

Niesvizky, Ruben, primary, Mark, Tomer M., primary, Ward, Maureen, primary, Jayabalan, David S., primary, Pearse, Roger N., primary, Manco, Megan, primary, Stern, Jessica, primary, Christos, Paul J., primary, Mathews, Lena, primary, Shore, Tsiporah B., primary, Zafar, Faiza, primary, Pekle, Karen, primary, Xiang, Zhaoying, primary, Ely, Scott, primary, Skerret, Donna, primary, Chen-Kiang, Selina, primary, Coleman, Morton, primary, and Lane, Maureen E., primary

Published
2023
Full Text
View/download PDF

21. Teachers as In-School Engineering Agents for Change.

Author

Alston, Christina Anlynette, Zafar, Faiza, Currier, Scott, Dunn, Krystle, Johnson, Milton, Verhofstad, Selene, and Nichol, Carolyn

Abstract

There is substantial evidence that most K-12 teachers who want to incorporate engineering design into their courses learn their skills independently or through an extracurricular professional development (PD) program. Regardless of the value of these PD programs, rookie teachers are frequently required to make personal sacrifices (e.g., time, money, and stress) to participate and thus hindering their long-term progress. To offer an alternative, four Teacher Leaders Engineering Network (TaLENt) fellows from primary and secondary schools served as change agents for novice engineering teachers for one academic year to promote the integration of engineering design in their classrooms. This research aimed to understand how school-based teacher leaders can support peer educators in authentically integrating engineering design within their core subjects. Our research questions were: 1) To what extent was the High-Quality Engineering Guidebook used within each TaLENt fellow's Project? 2) How did the TaLENt fellows characterize their values while collaborating with their novice peers? Employing a qualitative method, we used constant comparative analysis and triangulation to understand our collected datasets: TaLENt fellow narratives (N = 4 autobiographical texts), teacher project artifacts, and focus group transcripts. We found that TaLENt engineering PD increased peer collaboration, instructional risk-taking, and connections to cross-curricular subjects for novice teachers. Moreover, the action-based research approach paired with the High-Quality Engineering framework allowed inexperienced educators a say in their education, which helped reduce common misunderstandings about content alignment with engineering (such as the extent to which it applies to fields like physics or biology) and subsided anxiety about the processes of incorporating engineering in the classroom. The significance of this study is to highlight the value of teachers as in-school leaders. As states continue to adopt Next Generation Science Standards or incorporate engineering processes into their state-level curriculum, novice teachers will rely on their peers to strengthen their teaching practices within the subject, all while supporting the cultural needs of students. Our research shows the importance of in-school engineering PD facilitated by teacher leaders, especially for new and inexperienced engineering teachers; therefore, we recommend more investigation into implementing this type of PD. This change in professional development will make planning engineering lessons less stressful for novice teachers due to a reduced sense of isolation. [ABSTRACT FROM AUTHOR]

Published
2023

23. BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.

Author

Niesvizky, Ruben, Jayabalan, David S., Christos, Paul J., Furst, Jessica R., Naib, Tara, Ely, Scott, Jalbrzikowski, Jessica, Pearse, Roger N., Zafar, Faiza, Pekle, Karen, LaRow, April, Lent, Richard, Mark, Tomer, Cho, Hearn J., Shore, Tsiporah, Tepler, Jeffrey, Harpel, John, Schuster, Michael W., Mathew, Susan, Leonard, John P., Mazumdar, Madhu, Chen-Kiang, Selina, and Coleman, Morton

Published
2008
Full Text
View/download PDF

27. KarMMa-RW: A study of real-world treatment patterns in heavily pretreated patients with relapsed and refractory multiple myeloma (RRMM) and comparison of outcomes to KarMMa.

Author

Jagannath, Sundar, primary, Lin, Yi, additional, Goldschmidt, Hartmut, additional, Reece, Donna Ellen, additional, Nooka, Ajay K., additional, Rodríguez Otero, Paula, additional, Matsue, Kosei, additional, Shah, Nina, additional, Anderson, Jr, Larry D., additional, Wilson, Kimberly, additional, Swern, Arlene S., additional, Zafar, Faiza, additional, Agarwal, Amit Balkrishna, additional, and Siegel, David Samuel DiCapua, additional

Published
2020
Full Text
View/download PDF

30. Pomalidomide plus low‐dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure

Author

Siegel, David S., primary, Schiller, Gary J., additional, Song, Kevin W., additional, Agajanian, Richy, additional, Stockerl‐Goldstein, Keith, additional, Kaya, Hakan, additional, Sebag, Michael, additional, Samaras, Christy, additional, Malek, Ehsan, additional, Talamo, Giampaolo, additional, Seet, Christopher S., additional, Mouro, Jorge, additional, Pierceall, William E., additional, Zafar, Faiza, additional, Chung, Weiyuan, additional, Srinivasan, Shankar, additional, Agarwal, Amit, additional, and Bahlis, Nizar J., additional

Published
2019
Full Text
View/download PDF

31. Health-Related Quality of Life With Pomalidomide + Dexamethasone + Daratumumab After Lenalidomide in Relapsed or Refractory Multiple Myeloma Patients

Author

Reece, Donna, primary, Bahlis, Nizar J., additional, Samaras, Christy Joy, additional, Sebag, Michael, additional, Berdeja, Jesus, additional, Ganguly, Siddhartha, additional, Matous, Jeffrey, additional, Song, Kevin, additional, Seet, Christopher S., additional, Talamo, Giampaolo, additional, Acosta-Rivera, Mirelis, additional, Bar, Michael, additional, Quick, Donald, additional, Anz, Bertrand, additional, Fonseca, Gustavo, additional, Agarwal, Amit, additional, Chung, Weiyuan, additional, Zafar, Faiza, additional, and Siegel, David S., additional

Published
2019
Full Text
View/download PDF

32. A health-related quality-of-life (HRQoL) analysis of pomalidomide + low-dose dexamethasone + daratumumab in relapsed refractory multiple myeloma (RRMM) after lenalidomide treatment.

Author

Reece, Donna Ellen, primary, Bahlis, Nizar J., additional, Samaras, Christy Joy, additional, Sebag, Michael, additional, Berdeja, Jesus G., additional, Ganguly, Siddartha, additional, Matous, Jeffrey, additional, Song, Kevin W., additional, Seet, Christopher, additional, Talamo, Giampaolo, additional, Acosta-Rivera, Mirelis, additional, Bar, Michael, additional, Quick, Donald, additional, Anz, Bertrand Marquess, additional, Fonseca, Gustavo A., additional, Agarwal, Amit, additional, Chung, Weiyuan, additional, Zafar, Faiza, additional, and Siegel, David Samuel DiCapua, additional

Published
2019
Full Text
View/download PDF

33. Immune Profiling of Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide and Low-Dose Dexamethasone in Combination with Daratumumab

Author

Pierceall, William E., primary, Bahlis, Nizar, additional, Siegel, David S, additional, Schiller, Gary J., additional, Samaras, Christy J., additional, Sebag, Michael, additional, Berdeja, Jesus G., additional, Ganguly, Siddhartha, additional, Matous, Jeffrey V, additional, Song, Kevin, additional, Seet, Christopher S., additional, Talamo, Giampaolo, additional, Srinivas, Shanti, additional, Acosta-Rivera, Mirelis, additional, Bar, Michael, additional, Quick, Donald P., additional, Anz, Bertrand, additional, Fonseca, Gustavo, additional, Reece, Donna, additional, Chung, Weiyuan, additional, Serbina, Natalya, additional, Zafar, Faiza, additional, Agarwal, Amit, additional, and Thakurta, Anjan, additional

Published
2018
Full Text
View/download PDF

34. Pomalidomide + Low-Dose Dexamethasone + Daratumumab in Relapsed and/or Refractory Multiple Myeloma after Lenalidomide-Based Treatment Failure

Author

Siegel, David S, primary, Schiller, Gary J., additional, Samaras, Christy J., additional, Sebag, Michael, additional, Berdeja, Jesus G., additional, Ganguly, Siddhartha, additional, Matous, Jeffrey V, additional, Song, Kevin, additional, Seet, Christopher S., additional, Talamo, Giampaolo, additional, Acosta-Rivera, Mirelis, additional, Bar, Michael, additional, Quick, Donald P., additional, Anz, Bertrand, additional, Fonseca, Gustavo, additional, Reece, Donna, additional, Agarwal, Amit, additional, Chung, Weiyuan, additional, Zafar, Faiza, additional, and Bahlis, Nizar, additional

Published
2018
Full Text
View/download PDF

35. Health related quality of life for multiple myeloma patients according to treatment strategy after autologous stem cell transplant: a cross-sectional study using EORTC, EQ-5D and MY-20 scales

Author

Tay, Jason, primary, Vij, Ravi, additional, Norkin, Maxim, additional, Buadi, Francis, additional, Kindwall-Keller, Tamila L., additional, Roberts, Jenna S., additional, White, Darrell J., additional, Wood, Robert P., additional, Blanthorn-Hazell, Sophee E., additional, Rossi, Adriana C., additional, Dhanasiri, Sujith, additional, Zafar, Faiza, additional, Newhouse, Kim, additional, and McCurdy, Arleigh R., additional

Published
2018
Full Text
View/download PDF

37. Pomalidomide (POM) + low-dose dexamethasone (LoDEX) + daratumumab (DARA) in relapsed and/or refractory multiple myeloma (RRMM) after lenalidomide (LEN)-based treatment (Tx) failure.

Author

Siegel, David Samuel DiCapua, primary, Schiller, Gary J., additional, Samaras, Christy Joy, additional, Sebag, Michael, additional, Berdeja, Jesus G., additional, Ganguly, Siddhartha, additional, Matous, Jeffrey, additional, Song, Kevin W., additional, Seet, Christopher, additional, Talamo, Giampaolo, additional, Srinivas, Shanthi, additional, Acosta-Rivera, Mirelis, additional, Bar, Michael, additional, Quick, Donald, additional, Anz, Bertrand Marquess, additional, Fonseca, Gustavo, additional, Reece, Donna Ellen, additional, Zafar, Faiza, additional, Chung, Weiyuan, additional, and Bahlis, Nizar J., additional

Published
2018
Full Text
View/download PDF

38. Impact of t(11;14) on outcomes in African American (AA) and non-AA (NAA) patients (Pts) with newly diagnosed multiple myeloma (NDMM): Connect MM registry.

Author

Gasparetto, Cristina, primary, Abonour, Rafat, additional, Jagannath, Sundar, additional, Durie, Brian G., additional, Shah, Jatin J., additional, Narang, Mohit, additional, Terebelo, Howard R., additional, Toomey, Kathleen, additional, Hardin, James, additional, Wagner, Lynne I., additional, Srinivasan, Shankar, additional, Kitali, Amani, additional, Flick, E. Dawn, additional, Zafar, Faiza, additional, Agarwal, Amit, additional, and Rifkin, Robert M., additional

Published
2017
Full Text
View/download PDF

39. Treatment outcomes and healthcare resource utilization (HRU) in patients (Pts) with newly diagnosed multiple myeloma (NDMM) with lenalidomide (LEN) only or no maintenance: Connect MM registry.

Author

Rifkin, Robert M., primary, Jagannath, Sundar, additional, Durie, Brian G., additional, Shah, Jatin J., additional, Narang, Mohit, additional, Terebelo, Howard R., additional, Gasparetto, Cristina, additional, Toomey, Kathleen, additional, Hardin, James W., additional, Wagner, Lynne I., additional, Parikh, Kejal, additional, Abouzaid, Safiya, additional, Srinivasan, Shankar, additional, Kitali, Amani, additional, Zafar, Faiza, additional, and Abonour, Rafat, additional

Published
2017
Full Text
View/download PDF

40. Impact of post-autologous stem cell transplant (ASCT) maintenance therapy on outcomes in patients (Pts) with newly diagnosed multiple myeloma (NDMM) using the large prospective community-based Connect MM registry.

Author

Jagannath, Sundar, primary, Abonour, Rafat, additional, Durie, Brian G., additional, Shah, Jatin J., additional, Narang, Mohit, additional, Terebelo, Howard R., additional, Gasparetto, Cristina, additional, Toomey, Kathleen, additional, Hardin, James W., additional, Wagner, Lynne I., additional, Agarwal, Amit, additional, Srinivasan, Shankar, additional, Kitali, Amani, additional, Zafar, Faiza, additional, Sturniolo, Michael, additional, and Rifkin, Robert M., additional

Published
2017
Full Text
View/download PDF

41. Treatment Patterns From 2009-2015 in Patients With Newly Diagnosed Multiple Myeloma in the United States: A Report From the Connect® MM Registry

Author

Rifkin, Robert, primary, Abonour, Rafat, additional, Durie, Brian, additional, Gasparetto, Cristina, additional, Jagannath, Sundar, additional, Narang, Mohit, additional, Shah, Jatin, additional, Terebelo, Howard, additional, Toomey, Kathleen, additional, Kitali, Amani, additional, Zafar, Faiza, additional, Srinivasan, Shankar, additional, and Hardin, James, additional

Published
2017
Full Text
View/download PDF

42. Treatment Patterns from 2009 to 2015 in Patients with Newly Diagnosed Multiple Myeloma in the United States: A Report from the Connect® MM Registry

Author

Rifkin, Robert M., primary, Abonour, Rafat, additional, Durie, Brian G.M., additional, Gasparetto, Cristina J., additional, Jagannath, Sundar, additional, Narang, Mohit, additional, Shah, Jatin J., additional, Terebelo, Howard R., additional, Toomey, Kathleen, additional, Kitali, Amani, additional, Zafar, Faiza, additional, Srinivasan, Shankar, additional, and Hardin, James W., additional

Published
2016
Full Text
View/download PDF

43. Study of Analgesic Activity of Methanolic Extracts of Cuminum Cyminum (L.) and Centratherum Anthelminticum (L.) in Mice.

Author

Mahmood, Raana, Jawed, Itrat, Nosheen, Najam, Raheela, Anjum, Nargis, Sayeed, Bushra Z., and Zafar, Faiza

Subjects
CUMIN, DIMETHYL sulfoxide, ELLAGIC acid, MICE, EXTRACTS, ANIMAL housing
Abstract

Objective: This study was conducted to investigate and compare the analgesic activity of methanolic extracts of seeds of Cuminum Cyminum (L) and Centratherum anthelminticum (L)in mice. Methods: This study was conducted in the department of Pharmacology University of Karachi; 30 healthy mice were selected from animal house of Pharmacology department of University of Karachi for the study. All animals were divided into three groups, each group of 10 mice. Mice of Group 1 were given DMSO (Dimethyl sulphoxide) an organic solvent, mice of group 2 were given Methanolic extract of Cuminum Cyminum (L) and mice of group 3 were given Methanolic extract of Centratherum anthelminticum (L). The analgesic activity was investigated by tail flick test, heat is used to stimulate pain and observe analgesic activity, after a week of oral dosing of Methanolic extracts of seeds of Cuminum Cyminum (L) and Centratherum anthelminticum (L) in mice. Methanolic extracts of Cuminum Cyminum (L) and Centratherum anthelminticum (L) were insoluble in water so Dimethyl sulphoxide (DMSO) i.e. an organic solvent was used in this study (it is used for solutes that are insoluble in water). The methanolic extracts of Cuminum cyminum(L), Centratherum anthelminticum (L) and DMSO (dimethyl sulphoxide) were administered orally to three groups of mice for a week and on 7th day of dosing analgesic activity was tested through tail flick test, response is checked after 30, 60, 90, 120, 150, 180 and 240 minutes of 7th day of dosing. Results: The group of mice, which were given Methanolic extract of Cuminum cyminum(L)showed highly significant analgesic activity after 60, 90, 120, 150, 180 and 240 minutes of dosing. The group of mice which was given Methanolic extract of Centratherum anthelminticum (L) showed significant analgesic activity after 60, 90, 120, 150, 180 andhighly significant analgesic activity after 240 min. of dosing on 7th day. Conclusion: The results indicate that both extracts of Cuminum Cyminum (L) and Centratherum anthelminticum (L)showed analgesic activity. On comparison Cuminum Cyminum (L) have more superior analgesic potential than Centratherum anthelminticum (L). [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

44. Health related quality of life for multiple myeloma patients according to treatment strategy after autologous stem cell transplant: a cross-sectional study using EORTC, EQ-5D and MY-20 scales.

Author

Tay, Jason, Vij, Ravi, Norkin, Maxim, Buadi, Francis, Kindwall-Keller, Tamila L., Roberts, Jenna S., White, Darrell J., Wood, Robert P., Blanthorn-Hazell, Sophee E., Rossi, Adriana C., Dhanasiri, Sujith, Zafar, Faiza, Newhouse, Kim, and McCurdy, Arleigh R.

Subjects
STEM cell transplantation, MULTIPLE myeloma, QUALITY of life, CROSS-sectional method, ORGANIZATIONAL research
Abstract

Maintenance (MT) may be prescribed after autologous stem cell transplant (ASCT) but there are often concerns about the impact on quality of life (QoL). QoL was compared between baseline patients (30–100 days post-ASCT and had not commenced MT); MT patients (>100 days post-ASCT and receiving MT), and no MT (>100 days post-ASCT and not receiving MT). Patients completed the EuroQoL five dimension (EQ-5D), the European Organization for Research and Treatment of Cancer QoL Questionnaire Core 30 (EORTC QLQ-C30), and the QoL Questionnaire Myeloma 20 module (QLQ-MY20). Differences between groups were explored with ordinary least squares regressions. Across US and Canada, 303 patients participated. Regression analyses found few differences between MT and no MT. Only diarrhea (EORTC-QLQ C30) and future perspectives (MY-20) domains differentiated; patients on MT scored worse for diarrhea (+9.43; p =.0358) and future perspectives (−11.39; p =.0196). Collectively, the results suggest that MT is not associated with a notable QoL detriment. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

47. Immune Profile of Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) in the Second Line Immediately after Lenalidomide (LEN)

Author

Qian, Xiaozhong, Newhall, Kathryn, Tometsko, Mark, Bjorklund, Chad, Ma, Jianglin, Bahlis, Nizar J., Siegel, David, Schiller, Gary J., Samaras, Christy, Sebag, Michael, Berdeja, Jesus G., Ganguly, Siddhartha, Matous, Jeffrey V., Song, Kevin W, Seet, Christopher S., Talamo, Giampaolo, Srinivas, Shanthi, Acosta-Rivera, Mirelis, Bar, Michael, Quick, Donald, Anz, Bertrand, Fonseca, Gustavo, Reece, Donna, Mouro, Jorge, Agarwal, Amit, Zafar, Faiza, and Thakurta, Anjan

Published
2017
Full Text
View/download PDF

49. Safety and Efficacy of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) As Second- or Third-Line Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) after Lenalidomide (LEN)-Based Treatment (Tx) Failure

Author

Siegel, David, Schiller, Gary J., Samaras, Christy, Sebag, Michael, Berdeja, Jesus G., Ganguly, Siddhartha, Matous, Jeffrey V., Song, Kevin W, Seet, Christopher S., Talamo, Giampaolo, Srinivas, Shanthi, Acosta-Rivera, Mirelis, Bar, Michael, Quick, Donald, Anz, Bertrand, Fonseca, Gustavo, Reece, Donna, Mouro, Jorge, Agarwal, Amit, Zafar, Faiza, Qian, Max, Thakurta, Anjan, and Bahlis, Nizar J.

Published
2017
Full Text
View/download PDF

50. Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) Safety and Efficacy in Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Previously Treated with a Proteasome Inhibitor (PI) and in Whom Last Prior Therapy with Lenalidomide (LEN) Failed

Author

Siegel, David, Schiller, Gary J., Song, Kevin W, Agajanian, Richy, Stockerl-Goldstein, Ketih, Kaya, Hakan, Sebag, Michael, Samaras, Christy, Malek, Ehsan, Talamo, Giampaolo, Seet, Christopher S., Mouro, Jorge, Zafar, Faiza, Chung, Weiyuan, Srinivasan, Shankar, Qian, Max, Agarwal, Amit, Thakurta, Anjan, and Bahlis, Nizar J.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results